6071-92-7

Basic information

• Product Name: (1-methylpiperidin-4-yl)(diphenyl)methanol
• Synonyms: .alpha.,.alpha.-Diphenyl-1-methyl-4-piperidinemethanol; 4-Piperidinemethanol, .alpha.,.alpha.-diphenyl-1-methyl-
• CAS NO: 6071-92-7
• Molecular Formula: C₁₉H₂₃NO
• Molecular Weight: 281.392
• Mol File: 6071-92-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 421.5°C at 760 mmHg
• Flash Point: 202°C
• Density: 1.093g/cm³
• Vapor Pressure: 7.38E-08mmHg at 25°C
• Refractive Index: 1.583
• CAS DataBase Reference: (1-methylpiperidin-4-yl)(diphenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1-methylpiperidin-4-yl)(diphenyl)methanol(6071-92-7)
• EPA Substance Registry System: (1-methylpiperidin-4-yl)(diphenyl)methanol(6071-92-7)

Safety Data

• Hazardous Substances Data: 6071-92-7(Hazardous Substances Data)

Usage

General Description

The chemical (1-methylpiperidin-4-yl)(diphenyl)methanol is an organic compound with a molecular formula of C21H25NO. It is a tertiary alcohol with a piperidine ring and two phenyl groups attached to the carbon atom. (1-methylpiperidin-4-yl)(diphenyl)methanol may be used in various chemical reactions and organic synthesis processes. It may also have potential applications in the pharmaceutical industry, particularly in the development of new drugs and medications. Additionally, it is important to handle this compound with care, as it may have potential health and safety hazards if not used properly.

Upstream product

• 7440-32-6 titanium 
• 58258-01-8 4-diphenylmethoxypiperidine 
• 5570-77-4 4-chloro-1-methylpiperidine 
• 119-61-9 benzophenone 
• 14548-46-0 4-Benzoylpyridine 
• 113012-26-3 4-(hydroxy-diphenyl-methyl)-1-methyl-pyridinium iodide 
• 1620-30-0 diphenyl(pyridin-4-yl)methanol 
• 1557-31-9 N-methyl-4-benzylpiperidine 
• 68947-43-3 1-methylpiperidine-4-carboxylic acid 
• 34285-40-0 4-benzoyl-1-methylpyridinium iodide 
• 92196-29-7 (1-methylpiperidin-4-yl)(phenyl)methanol 
• 20735-04-0 (1,2,3,6-tetrahydro-1-methylpyridin-4-yl)diphenylmethanol 
• 50-00-0 formaldehyd 
• 115-46-8 C₁₈H₂₁NO 

Downstream Products

• 112818-77-6 ethyl 4-(hydroxydiphenylmethyl)piperidine-1-carboxylate 
• 115-46-8 C₁₈H₂₁NO 
• 950054-08-7 (1-benzenesulfonylpiperidin-4-yl)diphenylmethanol 
• 852860-46-9 diphenyl[1-(toluene-4-sulfonyl)piperidin-4-yl]methanol 
• 1152785-34-6 [1-(2-nitrobenzenesulfonyl)piperidin-4-yl](diphenyl)methanol 
• 1164112-38-2 (1-(3,5-dimethyl-2,3-dihydro-isoxazole-4-sulfonyl)-piperidin-4-yl)-diphenyl-methanol 
• 1164112-40-6 [1-(4-propylbenzenesulfonyl)piperidin-4-yl]diphenylmethanol 
• 1164112-41-7 diphenyl[1-(propane-2-sulfonyl)piperidin-4-yl]methanol 
• 1032324-37-0 [1-((4-chloro-2-fluorobenzene)sulfonyl)piperidin-4-yl]diphenylmethanol 
• 1164112-42-8 [1-(butane-1-sulfonyl)piperidin-4-yl]diphenylmethanol 
• 1164112-43-9 (1-chloromethanesulfonylpiperidin-4-yl)diphenylmethanol 
• 1164112-44-0 diphenyl(1-phenylmethanesulfonylpiperidin-4-yl)methanol 
• 1164112-45-1 [1-(3-nitro-benzene-1-sulfonyl)piperidin-4-yl]diphenylmethanol 
• 1164112-46-2 [1-(4-nitrobenzene-1-sulfonyl)piperidin-4-yl]diphenylmethanol 

Relevant articles and documents

-

-

Synthesis and in vitro antiproliferative activity of diphenyl(sulphonylpiperidin-4-yl)methanol derivatives

A series of novel diphenyl(piperidin-4-yl)methanol derivatives 10(a-n) were synthesized and characterized by 1H NMR, LC/MS, FTIR, and elemental analyses. All the synthesized compounds were evaluated for cell proliferation by MTT assay. The antiproliferative effects of the synthesized compounds were tested against viable human skin fibroblast cell line and carcinoma cell lines, namely HeLa cells, HT-29 cells, MCF-7 cells, and HepG-2 cells in comparing the positive and negative control. Among the synthesized compounds, (10b) and (10g) have been identified as potent antiproliferative agents.

TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS

The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of derivatized, e.g., ester or carboxylic acid derivatized, antihistamine antagonists for the treatment of sleep disorders.